Savara to present new IMPALA trial analysis of molgramostim in aPAP at CHEST 2026
SVRA•Savara said it will present new analyses of molgramostim from its IMPALA and IMPALA-2 trials in autoimmune pulmonary alveolar proteinosis at CHEST 2026.
1. Planned trial analyses
Savara said it will present long-term open-label data from IMPALA-2 focused on sustained efficacy and safety, as well as an IMPALA analysis highlighting treatment effects in patients with milder disease-related diffusion impairment.
